Benfotiamiini tiedekirjallisuudessa

Click on the authors´ names or the indicated links to view the articles/abstracts

Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab. 2007;9(3):233-45. [Free Full Text, pdf]

Anisimova EI, Danilov AB. [Benfotiamine efficacy in alcoholic polyneuropathy therapy] Zh Nevrol Psikhiatr Im S S Korsakova. 2001;101(12):32-6. Russian

Anonymous. Diabetic complications: emerging themes and treatment options. Inpharma 2001;1(1310) 11-12 [Ingenta Connect]

Anonymous: Benfotiamine prevents diabetic retinopathy. Inpharma 2003;1(1386) 6 [Ingenta Connect]

Arora S, Lidor A, Abularrage CJ, et al. Thiamine (vitamin B(1)) improves endothelium-dependent vasodilatation in the presence of hyperglycemia. Annals of Vascular Surgery 2006 20(5):653-8 [Abstract]

Ayazpoor U. [Chronic alcohol abuse. Benfotiamine in alcohol damage is a must] MMW Fortschr Med. 2001 Apr 19;143(16):53. German. No abstract available.

Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes. 2003;52(8):2110-20.[Abstract] [Free Full Text, pdf]

Balakumar P, Sharma R, Singh M. Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacol Res. 2008 Oct 2. Epub ahead of print

Baynes JW, Monnier VM, Ames JM, Thorpe SR (eds). The Maillard Reaction: Chemistry at the interface of nutrition, aging, and disease. Ann N Y Acad Sci 2005; 1043: 784–792. doi: 10.1196/annals.1333.091

Beltramo E, Nizheradze K, Berrone E, et al. Thiamine and benfotiamine prevent apoptosis induced by high glucose-conditioned extracellular matrix in human retinal pericytes. Diabetes Metab Res Rev. 2009 Sep 18. [Epub ahead of print] http://tinyurl.com/ya7j3uq

Beltramo E, Berrone E, Buttiglieri S, Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev. 2004;20(4):330-6.[Abstract]

Beltramo E, Berrone E, Tarallo S, Porta M. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol. 2008 DOI 10.11007/s00592-008-0042-y] [Free Full Text]

Beltramo E, Berrone E, Tarallo S, Porta M. Different apoptotic responses of human and bovine pericytes to fluctuating glucose levels and protective role of thiamine. Diabetes Metab Res Rev. 2009 Jul 10. [Epub ahead of print]

Bergfeld R, Matsumara, Du X, Brownlee M. Benfotiamin prevents the consequences of hyperglycemia-induced mitochondrial overproduction of reactive oxygen species, and experimental diabetic retinopathy. [Abstract]

Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem. 2006;7;281(14):9307-13.[Abstract] [Free Full Text]

Berrone E, Tarallo S, Porta M. Effects of thiamine and benfotiamine on intracelular glucose metabolism and relevance in the prevention of diabetic comoplicatyions. Acta Diabetologica 2008 June 26 [Free Full Text online]]

Bloomgarden ZT. American Diabetes Association 60th Scientific Sessions, 2000: Nephropathy. Diabetes Care 24: 598-601. [Full Text] [PDF] Taustatietoja kirjoittajasta

Bloomgarden ZT. Diabetes Complications. Diabetes Care 2004;27: 1506-1514. [Free Full Text,html] [PDF]

Bloomgarden ZT. The European Association for the Study of Diabetes. Diabetes Care 2005;28:1250-1257. [Free Full Text, html] [PDF]

Bloomgarden ZT. Weight Control in Individuals With Diabetes. Diabetes Care2006; 29: 2749-2754. [Full Text] [PDF]

Bloomgarden ZT. Atypical Antipsychotic Agents, Retinopathy, Nephropathy, and Cardiovascular Disease Diabetes Care 2006;29: 1439-1446. [Full Text] [PDF]

Bloomgarden ZT. Diabetic Retinopathy and Neuropathy. Diabetes Care 2006;28: 963-970. [Full Text] [PDF]

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-25. [Free Full Text]

Breb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. Int J Clin Pharmacol Ther. 1998;36(4):216-21 [PubMed].

Cameron NE, Gibson TM, Nahgle MR, Cotter MA. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann N Y Acad Sci 2005;1043:784-92. Review [Abstract]

Coy JF, Dressler D, Wilde J, Schubert P. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab . 2005;51(5-6):257-73 [PubMed]

Ceylan-Isik AF, Wu S, Li Q, Li SY, Ren J. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol. 2006;100(1):150-6.

Dandona P, Chaudhuri A, Mohanty P. Macronutrients, advanced glycation end products, and vascular reactivity. Editorial. Diabetes Care. 2007;30(10):2750-1 [pdf]

Di Rocco M, Patrini C, Rimini A, Rindi G. A 6-month-old girl with cardiomyopathy who nearly died. Lancet. 1997;349(9052):616. No abstract available.

Du X, Edelstein D, Brownlee M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008 July 29. [Epub ahead of print]

Forbes JM, Fukami K, Cooper ME. iabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes. 2007;115 (2): 69-84 . Review. [Full Free Text]

Frank T, Bitsch R, Maiwald J, Stein G. High thiamine diphosphate concentration in erythrocytes can be achieved in dialysis patients by oral adnministratyion of benfotiamine. Eur J Clin Pharmacol 2000;56(3):251-7 [PubMed]

Fujiwara M, Sasakawa S, Itokawa Y, Ikeda K. Affinity of thiamine propyl disulphide-S35 to organs. J Viaminol (Kyoto) 1964;10:79–87.

Fujiwara M. Allithiamine and itsproperties. J. Nutr Sci Vitaminol (Kyoto) 1976;22 (Suppl):57–62

Fujiwara M. Absorption, excretion and fate of thiamine and its derivatives in [the] human body. Chapter in: Shimazono N, Katsura, eds: Beriberi and Thiamine. 1965, Tokyo, Igaku Shoin Ltd. pp.179-213.

Gadau S, Emanueli C, Van Linthout S, et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia. 2006;49(2):405-20.[Abstract]

Giusti C, Gargiulo P. Advances in biochemical mechanisms of diabetic retinopathy. Eur Rev Med Pharmacol Sci . 2007; 11 ( 3 ): 155-63 . Review. [PubMed] [Free Full Text, pdf]

Goepp JG. Protecting against glycation and high blood sugar with benfotiamine. Review. Life Extension 2008;4:55–61 [Free Full Text pdf]

Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. Int J Clin Pharmacol Ther. 1998;36(4):216-21 [PubMed]

Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care 2005;28(1):164-176 [Free Full Text]

Hammes H-P, Brerzel RG, Federlin K et al. Benfotiamin inhibits the formation of advanved glycation end products in diabetic rats [Poster]

Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine 2003;9(3):294-9 [Abstract]

Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. American Journal of Ophthalmology 2003;136(4) 787 [Ingenta Connect]

Haupt E, Ledermann, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy – a three-week randomized, controlled pilot study (BEDIP Study.) International Journal of Clinical Pharmacology and Therapeutics. 2005;34 (2), 71-77 [Abstract]

Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev. 2006;11(4):294-329 [Free Full Text]

Hillbom M, Pyhtinen J. Tiamiinivajeen diagnostiikka ja hoito. Duodecim. 2000;116(7):749-53 [Free Full Text html] [pdf]

Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JEB. Diabetes and advanced glycoxidation end products. Diabetes Care, 2006; 29(6): 1420- 1432 [Free Full Text, html][PDF]

Jermendy G. Evaluating thiamine deficiency in patients with diabetes. Diab Vasc Dis Res. 2006;3(2):120-1.[Free Full Text, pdf]

Kaneto H, Xu G, Song KH, et al. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J Biol Chem. 2001;276(33):31099-104 [Free Full Text]

Karachalias N, Babaei-Jadidi R, Kupich C, Ahmed N, Thornalley PJ. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci. 2005;1043:777-83 [Abstract]

Kempler P. [ Treatment of neuropathies] Orv Hetil. 2004;23;145(21):1145-7. Review. Hungarian.

Kiefer D. Benfotiamine. European supplement protects against diabetic complications. Life Extension Magazine 2007;1. Free Full Text

Lin J, Tan S, Liersch J et al. Benfotiamin hemmt die intrazelluläre Bilding von Glykierungsfolgeprodukten in-vivo. Poster

Lin J, Alt A, Liersch J, Bretzel RG, Brownlee MA, Hammes HP. Benfotiamin inhibits intracellular formation of advanced Glycation endproducts in vivo. Diabetes. 2000; 49(Suppl1): A143(P583).

Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther. Review 1996;34(2):47-50.

Lüttke A. Benfotiamin schützt vor schädlichen AGEs. Deutsches Diabetes-Zentrum DDZ Düsseldorf 2006 [Full Free Text]

Ma H, Li SY, Xu P, Babcock SA, Dolence EK, Brownlee M, Li J, Ren J. Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) upregulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med. 2008 Oct 13. [Epub ahead of print]

Malecka SA, Poprawski K, Bilski B. [Prophylactic and therapeutic application of thiamine (vitamin B1)--a new point of view] Wiad Lek. 2006;59(5-6):383-7. Review. Polish.

Manuilov OE, Bezzubenko LA. Milgamma in the treatment of chronic neurosensory hypoacusis] Vestn Otorinolaringol. 2004;(5):47-8. Russian. No abstract available.

Marchetti V, Menghini R, Rizza S, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes. 2006;55(8):2231-7.[Free Full Text, html][PDF]

Medvedeva LA, Gnezdilov AV, Zagorul'ko OI, Syrovegin AV, Samoilova NV, Slashchuk IuI. [Neurometabolic therapy of diabetic neuropathy] Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(7):71-3. Russian. No abstract available.

Nakamura J. [Development of therapeutic agents for diabetic neuropathies] Nippon Rinsho. 2005;63 Suppl 6:614-21. Review. Japanese. No abstract available.

[No Authors Listed] Benfotiamine - monograph. Altern Med Rev. 2006;11(3):238-242. [Free Full Text]

[No authors listed] [Diabetes mellitus. Retinal lesions should not exist!] MMW Fortschr Med. 2004;146(5):53. German. No abstract available.

[No authors listed] [Oral benfotiamine therapy. Thus you protect the nerves of diabetic patients] MMW Fortschr Med. 2004;146(5):52-3. German. No abstract available.

Oh SH, Witek RP, Bae SH, et al. Detection of transketolase in bone marrow-derived insulin producing cells: Benfotiamine enhances insulin synthesis and glucose metabolism. Stem Cells Dev. 2008 Apr 7; [Epub ahead of print]

Obrenovich ME, Monnier VM. Vitamin B1 blocks damage caused by hyperglycemia. Sci Aging Knowledge Environ. 2003;2003(10):PE6.

Price DL, Rhett PM, Thorpe SR, Bayes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem. 2001;276(52):48967-72 [Free Full Text html,[ pdf]

Pomero F, Molinar Min A, La Selva M, Allione A, Molinatti GM, Porta M. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol. 2001;38(3):135-8 [Abstract]

Sadekov RA, Danilov AB, Vein AM. Diabetic polyneuropathy treatment by milgamma-100 preparation. Zh Nevrol Psikhiatr Im S S Korsakova. 1998;98(9):30-2. Russian. [Abstract]

Sanchez-Ramirez GM, Caram-Salas NL, Rocha-Gonzalez HI, et al. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol. 2006;530(1-2):48-53. [Abstract]

Schmid U, Stopper H, Heidland A, Schupp N. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes/Metabolism Research and Reviews April 2008 Online [Abstract].

Schupp N, Dette EM, Schmid U, et al. Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn Schmiedebergs Arch Pharmacol . 2008 May 29. [Free Full Text, pdf ]

Schupp N, Schmid U, Heidland A, Stopper H. New approaches for the treatment of genomic damage in end-stage renal disease. J Ren Nutr. 2008; 18 ( 1 ): 127-33 [PubMed]

Simeonov S, Pavlova M, Mitkov M, et al.. Therapeutic efficacy of "Milgamma" (benfotiamine) in patients with painful diabetic neuropathy. Folia Med (Plovdiv). 1997;39(4):5-10. [Abstract]

Sourris KC, Forbes JM, Cooper ME. Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome? Ann N Y Acad Sci . 2008; 1126:101-6 . Review. [ Free Full Text]

Stirban A, Negrean M, Stratmann B et al. Adiponectin decreases postprandially following a heat processed meal in people with Type 2 Diabetes - an effect prevented by Benfotiamine and cooking method. Diabetes Care Published Ahead of Print, published online on July 13, 2007 as dc07-0302 [Extract]

Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care. 2006;29(9):2064-71. [Free Full Text] [Reuters Health 22.9.2006]]

Stirban A, Negrean M, Gawlowski T, et al. Benfotiamin kann bei Patienten mit Typ 2 Diabetes mellitus (T2DM) dem akuten Anstieg der Serummarker der Endotheldysfunktion und oxidativem Stress induziert durch eine AGE-reiche (Advanced Glycation Endproducts) Mahlzeit vorbeugen. Diabetologie und Stoffwechsel 2006; 1 DOI: 10.1055/s-2006-943868 [Full Free Text]

Stirban A. Drugs for the treatment of diabetes complications. Zycose: A new player in the field? Drugs Today (Barc). 2008;44(10):783-96.

Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes. 1996;104(4):311-6.

Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, Geyer J, Kopcke W, Sauerland C, Bretzel RG, Federlin KF. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes. 2001;109(6):330-6.

Stracke H, Gaus W, Achenbach U, et al. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a Randomised, Double Blind, Placebo-controlled Clinical Study. Exp Clin Endocrinol Diabetes. 2008 May 13. [Epub ahead of print] [Free Full Text, pdf]

Suzuki S. [Role of mitochondrial dysfunction in pathogenesis of diabetic microangiopathy] Nippon Rinsho. 2005;63 Suppl 6:103-10. Review. Japanese. No abstract available.

Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets. 2005;6(4):453-74. Review. [Abstract]

Thornalley PJ. The potential role of thiamine (Vitamin B1) in diabetic complications. Current Diabetes Reviews 2005;1(3)287-298 [Abstract]

Thornalley PJ, Babaei-Jadedi R, Al Ali H, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007 Aug 4; [PubMed]

Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care. 2007;30(10):2579-82. [Abstract] [Artikkelin kopion voi tilata Bio-Vitasta.]

Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol. 2006;1(6):1293-9 [Abstract][Free Full Text, pdf]

Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes, Obesity and Metabolism, OnlineEarly Articles. Published online: 26-Jun-2007 doi: 10.1111/j.1463-1326.2007.00741.x [Abstract]

Wada T, Takagi H, Minakami H, Hamanaka W, Okamoto K, Ito A, Sahashi Y: A new thiamine derivative, S-benzoylthiamine O-monophosphate. Science 1961; 134 : 195-196. PubMed Abstract

Winkler G, Pál B, Nagybeganyi E, Ory I, Porochnavec M, Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung. 1999;49(3):220-4 [PubMed]

Woelk H, Lehrl S, Bitsch R, Kopcke W. Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study). Alcohol Alcohol. 1998;33(6):631-8. [Free Full Text]

Volvert ML, Seyen S, Piette M, Evrard B, Gangolf M, Plumier JC, Bettendorff L. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol . 2008 Jun 12; 8:10. [Free Full Text]

Wu S, Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett. 2006;394(2):158-62.[Abstract]

Yamagishi S, Imaizumi T. [Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors] Nippon Rinsho. 2005;63 Suppl 6:136-8. Review. Japanese. No abstract available.

Yao D, Taguchi T, Matsumura T, et al. Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription. Cell 2006; 124, 275–286 [Referred]

Yadav UCS, Subramanyam S, Ramana KV. Lipophilic Vitamin-B1 Analogue Benfotiamine Prevents Endotoxin-Induced Uveitis in Rats. Investigative Ophthalmology and Visual Science 2009 published online ahead of print January 10, 2009 DOI: 10.1167/iovs.08-281